An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) (AiiM OLE)

Annexon

Status and phase: Not yet enrolling; Phase 3

Conditions: Geographic Atrophy

Treatments: Drug: Vonaprument

Study type: Interventional

Funder types: Industry

Identifiers

NCT07807969

ANX007-GA-03

2026-527023-96-00 (EU Trial (CTIS) Number)

Details and patient eligibility

About

The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.

Enrollment: 605 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.

Exclusion criteria

• Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

605 participants in 1 patient group

Vonaprument

Experimental group

Description:

Participants will receive vonaprument IVT injections every month for 24 months.

Treatment:

Drug: Vonaprument